Scarica l'app Stockscreener
20.34
3.35%
0.66
Dopo l'orario di chiusura:
20.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$19.68
Aprire:
$19.76
Volume 24 ore:
1.14M
Relative Volume:
0.85
Capitalizzazione di mercato:
$2.49B
Reddito:
$460.48M
Utile/perdita netta:
$142.80M
Rapporto P/E:
17.24
EPS:
1.18
Flusso di cassa netto:
$221.79M
1 W Prestazione:
-8.46%
1M Prestazione:
-6.74%
6M Prestazione:
-10.40%
1 anno Prestazione:
+5.39%
Intervallo 1D:
$19.57
$20.36
Intervallo di 1 settimana:
$19.15
$22.53
Portata 52W:
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Confronta CPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.34 | 2.41B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharma Reports Record Q2 2025 Financial Results - The Globe and Mail
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years - 富途牛牛
Catalyst Pharmaceutical Partners Inc. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Catalyst Pharmaceuticals shares rise 1.70% premarket after Q2 revenue and adjusted EPS beat expectations. - AInvest
Catalyst Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Catalyst Pharmaceuticals reports Q2 EPS 68c, consensus 54c - TipRanks
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Catalyst Pharmaceuticals earnings beat by $0.29, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance - MarketScreener
Catalyst Pharmaceuticals Reports Record Second Quarter and - GlobeNewswire
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update - Yahoo Finance
Catalyst Pharmaceuticals Announces Inclusion of VGCC Antibody Testing and Amifampridine in NCCN Guidelines for Small Cell Lung Cancer-Associated LEMS - Quiver Quantitative
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing - GlobeNewswire
90% of SCLC Patients Miss LEMS Diagnosis: NCCN Updates Guidelines with Critical Testing Protocol - Stock Titan
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - MSN
Catalyst Pharmaceutics To Report Q2 Earnings: What's In The Cards? - Barchart.com
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - GlobeNewswire
Catalyst Pharma Appoints Dr. Curran to Board - TipRanks
Catalyst Pharmaceuticals Appoints Dr. Daniel Curran to Board of Directors - Quiver Quantitative
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Skyrocketing returns - Jammu Links News
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsMarket-leading capital gains - Jammu Links News
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyGet real-time alerts on high-potential stocks - Jammu Links News
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionDiscover stocks with superior performance - Jammu Links News
How does Catalyst Pharmaceuticals Inc. compare to its industry peersRealize consistent double-digit growth - Jammu Links News
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Game-changing capital returns - Jammu Links News
How strong is Catalyst Pharmaceuticals Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthUnlock rapid growth potential in your portfolio - Jammu Links News
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Exceptional stock performance - Jammu Links News
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockOutstanding stock performance - Jammu Links News
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedUnrivaled growth potential - Jammu Links News
Does Catalyst Pharmaceuticals Inc. stock perform well during market downturnsStock Strategy Insights For Fast Growth - Jammu Links News
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - Jammu Links News
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):